Slingshot members are tracking this event:

Teva and Eagle Pharmaceuticals Announce Commercial Availability of BENDEKA (bendamustine hydrochloride) Injection

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks



Additional Information

Additional Relevant Details Bendamustine hydrochloride injection, a liquid, low-volume (50 mL) and short-time 10-minute infusion formulation of bendamustine. BENDEKA is approved for the treatment of patients with chronic lymphocytic leukemia (CLL) and for the treatment of patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Efficacy in CLL relative to first-line therapies other than chlorambucil has not been established.

Under a February 2015 exclusive license agreement for BENDEKA, Teva is responsible for all U.S. commercial activities for the product including promotion and distribution.

Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 28, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Commercial Launch, Bendeka, Bendamustine Hydrochloride Injection, License Agreement, Distribution, Chlorambucil, B-cell Non-hodgkin Lymphoma, Nhl, Chronic Lymphocytic Leukemia, Cll